Longer-term Mortality and Kidney Outcomes of Participants in the Combination Antibiotics for Methicillin-Resistant Staphylococcus aureus (CAMERA2) Trial: A Post Hoc Analysis.
Amy LeggMatthew A RobertsJane DaviesAlan CassNiamh MeagherArchana SudVered DaitchYael Dishon BenattarDafna YahavMical PaulChen XinxinYeo He PingDavid LyeRussel LeeJ Owen RobinsonHong FooAdrian R TramontanaNarin BakAdelaide GrenfellBenjamin A RogersYing LiNeela JoshiMatthew O'SullivanGenevieve McKewNiladri GhoshKellie SchneiderNatasha E HolmesRavindra DotelTimothy ChiaSophia ArchuletaSimon SmithMorgyn S WarnerChristina TitinShirin KalimuddinJason Alexander RobertsSteven Y C TongJoshua Saul Davisnull nullPublished in: Open forum infectious diseases (2023)
bacteremia, we found no association between either treatment arm of the CAMERA2 trial or AKI (using CAMERA2 trial definition) and longer-term mortality.
Keyphrases
- methicillin resistant staphylococcus aureus
- phase iii
- study protocol
- phase ii
- clinical trial
- high speed
- preterm infants
- cardiovascular events
- convolutional neural network
- staphylococcus aureus
- risk factors
- open label
- randomized controlled trial
- gestational age
- type diabetes
- adipose tissue
- multidrug resistant
- machine learning
- deep learning
- gram negative
- skeletal muscle
- double blind
- placebo controlled